We are live on ! Find out more
AAA

Affinity Asset Advisors Portfolio holdings

AUM $2.21B
1-Year Est. Return 431.26%
This Fund
S&P 500
This Quarter Est. Return
+50.68%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$548M
AUM Growth
+$192M
Cap. Flow
+$47.8M
Cap. Flow %
8.74%
Top 10 Hldgs %
43.03%
Holding
102
New
19
Increased
25
Reduced
20
Closed
20

Top Buys

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$28M
2
LIAN
LianBio American Depositary Shares
LIAN
+$10.7M
3
NUVL
Nuvalent
NUVL
+$7.74M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.35M
5
ALKS icon
Alkermes
ALKS
+$6.66M

Top Sells

Rank Stock Value
1
APGE
Apogee Therapeutics
APGE
+$10.2M
2
KURA icon
Kura Oncology
KURA
+$6.54M
3
MORF
Morphic Holding, Inc. Common Stock
MORF
+$5.41M
4
PRTA icon
Prothena Corp
PRTA
+$3.82M
5
KRYS icon
Krystal Biotech
KRYS
+$3.6M

Sector Composition

Rank Sector Weight
1 Healthcare 86.38%
2 Miscellaneous 13.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IFRX icon
76
InflaRx
IFRX
$327M
$326K 0.06%
200,097
-125,000
-38% -$214K
PMN icon
77
ProMIS Neurosciences
PMN
$113M
$306K 0.06%
10,638
– –
ARAV
78
DELISTED
Aravive, Inc. Common Stock
ARAV
$42.9K 0.01%
346,511
– –
RCKTW
79
DELISTED
Rocket Pharmaceuticals Warrant
RCKTW
$36.8K 0.01%
75,000
– –
ACRS icon
80
PUT
Aclaris Therapeutics
ACRS
$908M
– –
-260,000
Closed -$1.78M
ALDX icon
81
Aldeyra Therapeutics
ALDX
$89.3M
– –
-44,348
Closed -$296K
ALKS icon
82
CALL
Alkermes
ALKS
$7.73B
– –
-200,000
Closed -$5.6M
APLS
83
PUT
DELISTED
Apellis Pharmaceuticals
APLS
– –
-130,000
Closed -$4.95M
ARKG icon
84
PUT
ARK Genomic Revolution ETF
ARKG
$2B
– –
-250,000
Closed -$6.96M
BCAB
85
DELISTED
BIOATLA INC
BCAB
– –
-3,600
Closed -$306K
ETNB
86
CALL
DELISTED
89bio
ETNB
– –
-37,300
Closed -$576K
IMVT icon
87
PUT
Immunovant
IMVT
$8.11B
– –
-128,100
Closed -$4.92M
INSP icon
88
Inspire Medical Systems
INSP
$1.82B
– –
-6,293
Closed -$1.25M
LNTH icon
89
Lantheus
LNTH
$6.59B
– –
-30,000
Closed -$2.08M
MESO
90
PUT
Mesoblast
MESO
$2.25B
– –
-200,000
Closed -$492K
MIST icon
91
Milestone Pharmaceuticals
MIST
$149M
– –
-335,068
Closed -$1.04M
NCEL
92
NewcelX Ltd
NCEL
$19.4M
– –
-501
Closed -$140K
PODD icon
93
Insulet
PODD
$10.2B
– –
-5,000
Closed -$797K
PRTA icon
94
Prothena Corp
PRTA
$504M
– –
-79,214
Closed -$3.82M
TVTX icon
95
Travere Therapeutics
TVTX
$6.15B
– –
-100,000
Closed -$894K
VKTX icon
96
PUT
Viking Therapeutics
VKTX
$4.07B
– –
-332,600
Closed -$3.68M
MORF
97
PUT
DELISTED
Morphic Holding, Inc. Common Stock
MORF
– –
-50,000
Closed -$1.15M
THRX
98
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
– –
-400,726
Closed -$1.08M
SGEN
99
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-10,000
Closed -$2.12M
1 2 3
4

Similar funds

BCP
BSN Capital Partners London, United Kingdom $2.21B AUM 22.85% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $2.21B AUM 39.6% 1-Year Est. Return
1SB
1ST Source Bank South Bend, Indiana $2.21B AUM 28.75% 1-Year Est. Return
CCA
Checchi Capital Advisers Beverly Hills, California $2.22B AUM 23.18% 1-Year Est. Return
MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2.22B AUM 32.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
LI
Leeward Investments Boston, Massachusetts $2.2B AUM 46.08% 1-Year Est. Return

Affinity Asset Advisors's Q4 2023 Portfolio in Review

As of Q4 2023, Affinity Asset Advisors held 102 positions worth $548M, up 54% from $356M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Affinity Asset Advisors deployed $47.8M of net new capital in Q4 2023, opening 19 new positions and adding to 25 existing holdings. Its largest new stake was Immunogen Inc: 1,404,608 shares worth $41.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 81% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Apogee Therapeutics, an estimated $10.2M trimmed.

  • Affinity Asset Advisors's largest Q4 2023 buy was Immunogen Inc: 1,404,608 shares worth $41.6M.
  • Affinity Asset Advisors added most to LianBio American Depositary Shares in Q4 2023, an estimated $10.7M increase.
  • Affinity Asset Advisors's biggest Q4 2023 reduction was Apogee Therapeutics, cutting an estimated $10.2M.
  • Affinity Asset Advisors fully exited Prothena Corp in Q4 2023, selling an estimated $3.82M.
  • Affinity Asset Advisors's ten largest holdings make up 43% of its $548M portfolio in Q4 2023.
  • Affinity Asset Advisors opened 19 new positions and closed 20 in Q4 2023.
  • Affinity Asset Advisors's portfolio value rose 54% quarter-over-quarter to $548M.

Based on Affinity Asset Advisors's 13F filing for Q4 2023, filed 13 Feb 2024.